US3159545A - Radioactive capsules - Google Patents

Radioactive capsules Download PDF

Info

Publication number
US3159545A
US3159545A US60312A US6031260A US3159545A US 3159545 A US3159545 A US 3159545A US 60312 A US60312 A US 60312A US 6031260 A US6031260 A US 6031260A US 3159545 A US3159545 A US 3159545A
Authority
US
United States
Prior art keywords
radioactive
oil
capsule
solid
wax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US60312A
Other languages
English (en)
Inventor
Kidwell Ralph Edward
Dalton Edward Robert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NL269886D priority Critical patent/NL269886A/xx
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority to US60312A priority patent/US3159545A/en
Priority to GB33882/61A priority patent/GB938828A/en
Priority to BE608721A priority patent/BE608721A/fr
Priority to FR883228A priority patent/FR1712M/fr
Application granted granted Critical
Publication of US3159545A publication Critical patent/US3159545A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1262Capsules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Definitions

  • This invention relates to radioactive capsules and particularly to capsules wherein radioactive compounds are retained without leakage.
  • An oil such as glycerol trioleate has been tagged with a radioactive material and has been used as a tool in the study of fat metabolism.
  • This radioactive isotope has been commonly deposited within a capsule and has been scaled therein by the simple step of telescoping a top capsule portion over a bottom portion of reduced diameter wherein is contained the radioactive oil.
  • This particular embodiment has serious disadvantages in that the oil can possibly leak from the contained capsule, thereby causing serious contamination and reduction of the radioactive energy content. The possibility of such leakage is present and likely in ordinary handling, but the disadvantage is compounded many times by the necessary presence of air freight transport.
  • a still further object of this invention is to provide ca sules suitable for oral administration wherein a liquid form of a radioactive compound is incorporated in a waxlike vehicle.
  • a radioactive compound is placed in a capsule with a vehicle which is a solid at below body temperatures (37 C.) and melts at higher temperatures. It has now been found that radioactive compounds can be incorporated in those vehicles commonly employed in the suppository art. Such combined vehicle and radioactive compound can then be placed in a capsule suitable for oral ingestion and retained therein as a solid state below body temperatures. This novel article of manufacture significantly decreases any contamination hazard and eliminates the leakage of the radioactive compound from within the capsule.
  • the radioactive compound is mixed with a suitable wax and oil of proper proportions so that the resulting mixture is a solid at temperatures lower than 37 C., but melts at temperatures at or above this level.
  • the novel pharmaceutical form is prepared by melting a suitable wax and oil, combining therein the desired radioactive compound, transferring the molten mixture into a capsule, allowing the molten mixture to cool into a solid form and, thereafter, encapsulating the capsule so that the solid vehicle and radioactive compound therein is entirely contained within the capsular walls.
  • the actual volume of molten mixture which is transferred to the capsule will be determined by the degree of radioactivity desired in the final product which, in turn, is determined by the amount of activity actually in the mixture 'on the day of preparation. Since radioactive decay constantly occurs, the procedure prescribes a preliminary assay of the molten mixture containing the radioactive source and thereafter selecting an appropriate volume of said mixture in order to provide a particular range of activity in the capsule on the day of preparation. Reference to standard decay curves for the particular radioactive source incorporated will enable the practitioner to prepare capsules which will contain a desired activity at some ascertained future date of use.
  • Such capsules can be handled with greater assurance of freedom from radioactive contamination and can be quickly transported by air or other means without the extraordinary handling precautions which were necessary prior hereto in order to guard against leakage.
  • Air transportation is now an added advantage because the lower temperatures of air flight make the wax-like vehicle harder, therefore, providing greater resistance to the damaged effects of lowered pressure.
  • the great advantages obtained in the handling of such capsules are worthwhile because the pharmaceutical form is beneficially absorbed and utilized by the human.
  • the attending clinician administers such a capsule to the patient and once the capsule reaches the stomach of the patient, the capsule material is disintegrated, the solid vehicle melts and the radioactive compound is absorbed.
  • the capsules comprising an element disclosed herein are composed of a non-toxic, therapeutic, water-soluble material such as gelatin, methyl cellulose, polyvinyl alcohol or other thermoplastic, water-soluble, non-toxic materials which are therapeutically acceptable.
  • the vehicle for the radioactive compounds is basically composed of a solid wax generally having melting points materially in excess of 37 C. and a solid oil which is of a lower melting point, but when mixed with the foregoing waxes in proper proportions results in a solid form which melts 1 larger amount of solid oil which melts at a lower level in order to obtain the resultant solid form at temperatures lower than 37 C.
  • the choice of the waxes and solid oils is within the ordinary skill of the man in the art, once he is apprised of the teachings of this invention.
  • oils and Waxes which are non-toxic and compatible with the human organism. He will next compound the oil and wax in the proper proportion to obtain a solid having the melting characteristics described herein.
  • Representative and useful oils are theobroma oil (cocoa butter), hydrogenated or partially hydrogenated vegetable and plant oils such as corn, palm kernel, cottonseed, peanut, saffiower, olive and other operable solid oils.
  • Suitable waxes are carbowax, spermaceti, glycerol monostearate, beeswax, cetyl alcohol and other suitable low or highmelting, non-toxic, pharmaceutical waxes.
  • Parts 9 theobroma oil 4 spermaceti 13 total parts spermaccti The principles of allegation are also applicable in the event more than two ingredients are intended for combination. An example would be the combination of two solid oils of differing melting points with a solid wax of still another melting point. Recourse may be made to standard pharmaceutical texts in order to ascertain the method for combining such mixtures into a final composition melting at about 37 C.
  • the radioactive compounds suitable for incorporation in the combination of the present invention are those compounds which have a known use after oral administration to the human. Such uses may either be diagnostic or therapeutic.
  • Radioactive compounds which have been administered orally to the human for numerous purposes are radioactive iodine, glycerol trioleate, oleic acid, triiodothyronine and others.
  • the radioisotopes which have a particular utility and which are prescribed orally can be determined by current recourse to the state of this dynamic art, for the new compounds which are tagged with radioactive atoms are constantly increasing in number and in application. If a particular radioisotope has been described in the art as an orally useful agent, then such compound can be incorporated in the novel combination disclosed herein.
  • radioactive forms which are particularly useful for the present embodiment are those which occur as oils,
  • oils such as glycerol trioleate and oleic acid.
  • These comall pounds are liquid oils and, therefore, are particularly adaptable to being incorporated directly in the oil-wax combination which comprises the solid vehicle.
  • the foregoing oils have unsaturated bonds in their chains which are suitably tagged with radioactive iodine
  • Other oils with double bonds can also be tagged with such radioactive isotopes, e.g., corn oil, sai'llower oil and the like.
  • oils tagged with radioactive iodine can be combined in equal volumes with the solid oil-wax combination which has been compounded to melt at 37 C. as set out hereinbefore.
  • the combination of an equal volume of oil with the solid vehicle compounded to melt at 37 C. does not significantly alter such melting point.
  • another inert oil can be employed as a diluent such as peanut oil or other vegetable oils. It is preferred to use an equal volume of the oil alone or diluted with another oil, which is to be combined with the solid vehicle because such volumes are easy to handle, easy to calculate and do not alter the melting point of the final composition.
  • the amount of oil added to the vehicle base is substantially greater than an equal volume, the resulting mixture tends not to form a firm solid melting in the desired range. Therefore, it is a preferred and well-advised practice to incorporate at least an equal volume of the vehicle base to the oil. Of course, lesser volumes of the oil will not significantly affect the desired melting point range even though the mass tends to become more firm.
  • radioactive materials which are not oils can also be incorporated in the wax-like vehicle to obtain similar advantages from the invention.
  • Such radioactive substances can be either a dry powder form which carries the radioactive compounds or suspensions and emulsions thereof.
  • Dry crystalline and powder forms can be incorporated directly into the wax-like vehicle by a mixing step.
  • a prepared vehicle base which melts at substantially 37 C., as illustrated hcreinbefore, is melted or softened by heat, and the dry radioactive form is placed therein and mixed. It is apparent that incorporating such dry forms into the present embodiments attains advantages in the subsequent handling and administration of the radioactive materials. Hazards of contamination from capsular leakage or damage are virtually eliminated while, concurrently, an elegant pharmaceutical form for oral administration is provided.
  • suspensions and emulsions of radioactive carriers can be incorporated into the embodiments of the present invention.
  • a practitioner may desire to employ suspensions rather than placing a waterinsoiuble material directly into the vehicle base as described hereinbefore.
  • Such suspensions can be prepared by conforming with the conventional procedures provided by that art and, thereafter, mixing said suspensions with the melted vehicle base.
  • Example I Ingredient: Amount Theobroma oil 4.753 gms. 8 1spermaceti 2.334 gms.
  • Glycerol triole'ate 1 tagged (1-2 mc./ml.)
  • the theobroma oil and spermaceti are melted on a steam bath at temperatures not exceeding 75 C.
  • the glycerol trioleate is added to this mixture and thoroughly mixed.
  • the combined volume of the theobroma and spermaceti is 8 ml. which results in a vehicle melting at about 37 C.
  • the melting point of the final composition is not altered from 37 C.
  • a volume of approximately 0.2 ml. of this melted mixture is removed by a pipette and transferred into a bottom half of a gelatin capsule while taking the conventional precautions against radiation hazards.
  • the upper half of the gelatin capsule is telescoped over the bottom portion and the melted mixture within the capsule is allowed to solidify.
  • the foregoing formulation provides a sufiicient amount of melted material to prepare about 80 gelatin capsules.
  • the solidified mixture melts in the range of 3436 C.
  • Each capsule contains an activity of about 50-100 ,uc. as calibrated to a future date of use or approximately 120 ,uC. of 1 activity as of day of preparation.
  • Example II Ingredient: Amount Glycerol monostearate 4 parts 1 Theobroma oil parts Glycerol trioleate, 1 tagged 4 ml.
  • Example II The procedure steps outlined in Example I are followed to prepare 40 gelatin capsules wherein each capsule contains an activity of about 50-100 [10. as calibrated to a future date of use.
  • Example III Ingredient: Amount Theobroma oil 4.753 gms. ⁇ 1spermaceti 2.334 gms.
  • Oleic acid 1 tagged (l-2 mc./m1.) 8 ml.
  • the theobroma and spermaceti are melted and combined with the oleic acid by process steps as described in Example I.
  • the combined melted mixture is placed in a syringe which is aflixed to a syringe microburet, Model SE22, manufactured by the Micro-metric Instrument Co. of Cleveland, Ohio.
  • a heating tape attached to a rheostat temperature control, is wrapped around the syringe to keep the waxes and oils in a molten state.
  • the syringe microburet has a manually motivated plunger arm which terminates at a position flush against the plunger arm of the syringe.
  • a dial is connected to the plunger systems whereby the desired volume of expelled molten solids can be determined. Volumes of approximately 0.2 ml. of expelled into each of the bottom portions of the gelatin capsules.
  • the opening of the top portion of the gelatin capsule is dipped in an alcoholic solution of polyvinylpyrrolidone and then telescoped over the bottom portion of the capsule containing the melted composition.
  • the alcoholic solution of polyvinylpyrrolidone serves to seal the capsule portions.
  • the foregoing formulation provides a suflicient amount of melted mate- 6 rial to prepare about gelatin capsules.
  • the solidified mixture melts in the range of 3234 C.
  • Each capsule contains an activity of about 50-100 ,uC. as calibrated to a future date of use.
  • An article of manufacture comprising a pharmaceutical capsule formed of a non-toxic, water-soluble, thermoplastic material and a radioactive composition compounded from pharmaceutical oils and waxes within said capsule, said radioactive composition being a liquid at about 37 C. and remaining a solid at lower temperatures.
  • An article of manufacture comprising a pharmaceutical capsule formed of a non-toxic, Water-soluble thermoplastic material containing therein a radioactive composition compounded from pharmaceutical oils and waxes, said composition containing a radioactive material that is liquid, said radioactive composition melting at about normal body temperatures and remaining substantially a solid at lower temperatures.
  • composition melting at body temperature is mixed with no more than an equal volume of Oil labeled with radioisotopes.
  • An article of manufacture according to claim 2 wherein the capsule is made of gelatin and the radioactive composition is compounded from theobroma oil and spermaceti wax.
  • said capsule is essentially composed of gelatin and said composition comprises theobroma oil, spermaceti wax and radioactive oleic acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
US60312A 1960-10-04 1960-10-04 Radioactive capsules Expired - Lifetime US3159545A (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
NL269886D NL269886A (pt) 1960-10-04
US60312A US3159545A (en) 1960-10-04 1960-10-04 Radioactive capsules
GB33882/61A GB938828A (en) 1960-10-04 1961-09-21 Improvements in or relating to pharmaceutical capsules comprising radioactive materials
BE608721A BE608721A (fr) 1960-10-04 1961-10-02 Capsules radioactives
FR883228A FR1712M (fr) 1960-10-04 1961-12-28 Capsules radioactives.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US60312A US3159545A (en) 1960-10-04 1960-10-04 Radioactive capsules

Publications (1)

Publication Number Publication Date
US3159545A true US3159545A (en) 1964-12-01

Family

ID=22028701

Family Applications (1)

Application Number Title Priority Date Filing Date
US60312A Expired - Lifetime US3159545A (en) 1960-10-04 1960-10-04 Radioactive capsules

Country Status (5)

Country Link
US (1) US3159545A (pt)
BE (1) BE608721A (pt)
FR (1) FR1712M (pt)
GB (1) GB938828A (pt)
NL (1) NL269886A (pt)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3421282A (en) * 1963-09-28 1969-01-14 Daiichi Kagaku Yakuhin Co Ltd Method for obtaining capsules having oily drugs closed therein
US3474777A (en) * 1966-02-10 1969-10-28 Amp Inc Method of administering therapeutic agents
US3670065A (en) * 1968-06-19 1972-06-13 Karl Gunnar Eriksson Process for producing dosage units of a type resembling tablets
FR2480124A1 (fr) * 1980-04-14 1981-10-16 Squibb & Sons Inc Capsules de diagnostic et therapeutiques et procede pour les fabriquer
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
EP0060434A2 (de) * 1981-03-13 1982-09-22 Akademie der Wissenschaften der DDR Verfahren zur Herstellung eines 131 Jod enthaltenden diagnostischen oder therapeutischen Mittels
US4505888A (en) * 1983-05-27 1985-03-19 E. I. Du Pont De Nemours & Company Tracer for circulation determinations
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5221535A (en) * 1989-11-13 1993-06-22 Nova Pharmaceutical Corporation Sustained release formulations of insect repellent
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5314678A (en) * 1992-01-28 1994-05-24 Mallinckrodt Medical, Inc. Sodium iodide 131 I capsules
US5340588A (en) * 1989-11-13 1994-08-23 Nova Pharmaceutical Corporation Liposphere carriers of vaccines
US5514869A (en) * 1994-02-22 1996-05-07 Martin, Jr.; James A. Method for estimating the probabilities of digestive tract doses due to the passage of a solid radioactive particle
US5993374A (en) * 1997-06-17 1999-11-30 Radiance Medical Systems, Inc. Microcapsules for site-specific delivery
WO2001064421A1 (en) * 2000-03-01 2001-09-07 Pvaxx Technologies Ltd. Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules
US20030201566A1 (en) * 1996-12-18 2003-10-30 Stevens Henry Guy Polymer processing method and tablet-forming apparatus
US7026375B1 (en) 1998-08-26 2006-04-11 Pvaxx Research And Development Limited PVA-containing compositions
US20060157054A1 (en) * 2005-01-11 2006-07-20 Boehringer Lngelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
US20080160076A1 (en) * 1998-08-05 2008-07-03 Dieter Hochrainer Two-part capsule to accept pharmaceutical preparations for powder inhalers

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29474E (en) * 1966-06-02 1977-11-15 Pharmacia Ab Method for the determination of proteins and polypeptides
GB1572226A (en) * 1977-11-03 1980-07-30 Hoechst Uk Ltd Pharmaceutical preparations in solid unit dosage form
FR2622110A1 (fr) * 1987-10-26 1989-04-28 Marty Georges Pile prevue pour l'utilisation du pouvoir radio-actif des plantes a des fins medicales
ITRM980488A1 (it) * 1998-07-23 2000-01-23 Nyl Service S R L Capsule autosigillanti e procedimento per la loro produzione

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2780355A (en) * 1953-11-09 1957-02-05 Scherer Corp R P Gelatin capsule containing water soluble substances
US2830010A (en) * 1956-05-14 1958-04-08 American Cyanamid Co Powder-filled hexylresorcinol capsules
US2911338A (en) * 1954-03-09 1959-11-03 Abbott Lab Capsules and method of producing
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
US2969331A (en) * 1958-06-04 1961-01-24 Ncr Co Process of making dual-walled oil containing capsules
US2973301A (en) * 1959-03-12 1961-02-28 Lloyd Brothers Inc Soft gelatin capsule

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2780355A (en) * 1953-11-09 1957-02-05 Scherer Corp R P Gelatin capsule containing water soluble substances
US2911338A (en) * 1954-03-09 1959-11-03 Abbott Lab Capsules and method of producing
US2830010A (en) * 1956-05-14 1958-04-08 American Cyanamid Co Powder-filled hexylresorcinol capsules
US2969331A (en) * 1958-06-04 1961-01-24 Ncr Co Process of making dual-walled oil containing capsules
US2956926A (en) * 1958-09-23 1960-10-18 American Cyanamid Co Coated citric acid particles
US2973301A (en) * 1959-03-12 1961-02-28 Lloyd Brothers Inc Soft gelatin capsule

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3421282A (en) * 1963-09-28 1969-01-14 Daiichi Kagaku Yakuhin Co Ltd Method for obtaining capsules having oily drugs closed therein
US3474777A (en) * 1966-02-10 1969-10-28 Amp Inc Method of administering therapeutic agents
US3670065A (en) * 1968-06-19 1972-06-13 Karl Gunnar Eriksson Process for producing dosage units of a type resembling tablets
FR2480124A1 (fr) * 1980-04-14 1981-10-16 Squibb & Sons Inc Capsules de diagnostic et therapeutiques et procede pour les fabriquer
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
EP0060434A2 (de) * 1981-03-13 1982-09-22 Akademie der Wissenschaften der DDR Verfahren zur Herstellung eines 131 Jod enthaltenden diagnostischen oder therapeutischen Mittels
EP0060434A3 (en) * 1981-03-13 1984-03-07 Akademie Der Wissenschaften Der Ddr Process for the preparation of a diagnostic or therapeutic composition containing iodine 131
US4505888A (en) * 1983-05-27 1985-03-19 E. I. Du Pont De Nemours & Company Tracer for circulation determinations
US4610868A (en) * 1984-03-20 1986-09-09 The Liposome Company, Inc. Lipid matrix carriers for use in drug delivery systems
US4663148A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising telescopically engaging members
US4663149A (en) * 1984-03-21 1987-05-05 Alza Corporation Dispenser comprising inner and outer walls functioning as cooperative unit
US4692326A (en) * 1984-03-21 1987-09-08 Alza Corporation Dispenser comprising inner positioned soft or hard capsule
US4716031A (en) * 1984-03-21 1987-12-29 Alza Corporation Drug dispenser comprising a multiplicity of members acting together for successfully dispensing drug
US5188837A (en) * 1989-11-13 1993-02-23 Nova Pharmaceutical Corporation Lipsopheres for controlled delivery of substances
US5221535A (en) * 1989-11-13 1993-06-22 Nova Pharmaceutical Corporation Sustained release formulations of insect repellent
US5227165A (en) * 1989-11-13 1993-07-13 Nova Pharmaceutical Corporation Liposphere delivery systems for local anesthetics
US5340588A (en) * 1989-11-13 1994-08-23 Nova Pharmaceutical Corporation Liposphere carriers of vaccines
US5314678A (en) * 1992-01-28 1994-05-24 Mallinckrodt Medical, Inc. Sodium iodide 131 I capsules
US5514869A (en) * 1994-02-22 1996-05-07 Martin, Jr.; James A. Method for estimating the probabilities of digestive tract doses due to the passage of a solid radioactive particle
US20030201566A1 (en) * 1996-12-18 2003-10-30 Stevens Henry Guy Polymer processing method and tablet-forming apparatus
US5993374A (en) * 1997-06-17 1999-11-30 Radiance Medical Systems, Inc. Microcapsules for site-specific delivery
US8298575B2 (en) 1998-08-05 2012-10-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule to accept pharmaceutical preparations for powder inhalers
US20080160076A1 (en) * 1998-08-05 2008-07-03 Dieter Hochrainer Two-part capsule to accept pharmaceutical preparations for powder inhalers
US7026375B1 (en) 1998-08-26 2006-04-11 Pvaxx Research And Development Limited PVA-containing compositions
AU2001235855B9 (en) * 2000-03-01 2006-01-12 Pvaxx Research And Development Limited Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules
AU2001235855B2 (en) * 2000-03-01 2005-08-04 Pvaxx Research And Development Limited Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules
US7195777B2 (en) 2000-03-01 2007-03-27 Pvaxx Research & Development Limited Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules
CN1321794C (zh) * 2000-03-01 2007-06-20 Pvaxx研究和开发有限公司 用于吹塑聚乙烯醇胶囊的方法和装置和吹塑的聚乙烯醇胶囊
US20030152619A1 (en) * 2000-03-01 2003-08-14 Stevens Henry Guy Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules
WO2001064421A1 (en) * 2000-03-01 2001-09-07 Pvaxx Technologies Ltd. Method and apparatus for blowmoding capsules of polyvinylalcohol and blowmolded polyvinylalcohol capsules
US20060157054A1 (en) * 2005-01-11 2006-07-20 Boehringer Lngelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers
US8662076B2 (en) 2005-01-11 2014-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Two-part capsule with pre-closure for housing pharmaceutical preparations for powder inhalers

Also Published As

Publication number Publication date
BE608721A (fr) 1962-04-02
FR1712M (fr) 1963-02-25
GB938828A (en) 1963-10-09
NL269886A (pt)

Similar Documents

Publication Publication Date Title
US3159545A (en) Radioactive capsules
US3139383A (en) Encapsulated time release pellets and method for encapsulating the same
CN1045884C (zh) 含有活性剂的高剂量制剂
US4450877A (en) Pharmaceutical preparations in solid unit dosage form
DE69505671T2 (de) Ein neues arzneimittelabgabesystem
JPS62114911A (ja) 経口投与型徐放性医薬製剤
US5976571A (en) Method for making a multi-stage drug delivery system
CA1057660A (en) Gelatin-encapsulated digoxin solutions and method of preparing the same
US3061510A (en) Radioactive iodinated (i131) fatty material admixed with wax-like material in capsule
EP0706381A1 (en) Soft-shelled gelatin encapsulated particles
US4761407A (en) Solid galenical form for oral administration, and the process for its preparation
SE512412C2 (sv) Farmaceutisk komposition i kapselform bestående av ranitidin och en icke-vattenhaltig grundmassa
US3663686A (en) Biodegradable radioactive particles
JPS6067416A (ja) ゲル組成物またはゲル含有組成物、およびその製法
US3121041A (en) Capsule containing a pharmaceutically useful radioactive material
DE2838387C2 (pt)
JPS60193913A (ja) 3―イソブチリル―2―イソプロピルピラゾロ〔1,5―a〕ピリジンの徐放性医薬品組成物
EP0042076B1 (en) Process for filling hard capsules with pharmaceutical products containing phospholipids and being highly viscous at room temperature
US6352717B2 (en) Process for encapsulating shear sensitive fill masses into capsules and capsules containing shear sensitive fill masses
US3927196A (en) Soluble capsules
JPS638327A (ja) ペレツトから構成されるモ−ルデイング
WO1999006031A1 (en) Pharmaceutical formulation for camptothecin analogues in gelatin capsule
US3159546A (en) Capsule sealing composition
DE3874320T2 (de) Tablette zur behandlung bei progesteronmangel.
Burns et al. An in vitro assessment of liquid-filled Capill® potato starch capsules with biphasic release characteristics